Selexys Pharmaceuticals Corporation Selects Cytovance Biologics for Process Development Services to Accelerate Development Programs

Published: Aug 01, 2007

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced that Selexys Pharmaceuticals Corporation has selected Cytovance for a range of process development services supporting acceleration of its anti-adhesion antibody programs.

Back to news